Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program ivps42019-11-04T19:41:33-05:00 Read More
Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019 ivps42019-10-30T13:20:39-05:00 Read More
Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference ivps42019-10-23T13:06:26-05:00 Read More
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study ivps42019-09-27T14:24:05-05:00 Read More
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference ivps42019-09-11T12:16:31-05:00 Read More
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial ivps42019-09-06T15:14:34-05:00 Read More
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences ivps42019-09-04T11:56:29-05:00 Read More
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update ivps42019-08-08T15:45:49-05:00 Read More
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019 ivps42019-07-29T12:55:39-05:00 Read More
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation ivps42019-07-22T11:08:59-05:00 Read More
